Clin2
NCT07565415Possibly a fitNot yet recruiting

Treatment for appetite loss in advanced liver cancer

Hepatocellular Carcinoma (HCC)CachexiaAnorexiaMalnutrition

Treatments studied

Part of Cancer, Digestive system, Hormones & metabolism clinical trials.

This trial tests whether a drug called nanocrystalline megestrol acetate can help improve appetite and weight loss in people with advanced liver cancer. It is given as a pill and is compared against a placebo (a pill with no active medicine).

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
88 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have liver cancer that cannot be removed by surgery.
  • You should not have received immunotherapy or targeted therapy before.
  • You need to have lost some weight without trying, or have a poor appetite.
  • You must be able to swallow pills and be in fairly good overall health (able to do light activities).
  • Your liver and kidney function should be within acceptable limits, as determined by blood tests.
  • You should not have other serious medical conditions or cancers.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07356037Not yet recruiting· Phase 3
Appetite-stimulating medication for advanced liver cancer with weight loss

This study tests a new form of megestrol acetate (a medication that helps stimulate appetite and weight gain) for people with advanced liver cancer who are experiencing weight loss or loss of appetite. It is given alongside standard treatments for liver cancer, and the goal is to see if it can improve appetite and quality of life.

Chengdu, Sichuan
NCT06940102Recruiting
A study on megestrol acetate for weight loss in advanced digestive cancer

This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).

Shenyang, Liaoning
NCT07338487Recruiting· Phase 1
Nanocrystalline megestrol acetate with chemoradiation for advanced cervical cancer

This trial tests a newer form of megestrol acetate (a medication that can help with appetite and weight) given alongside standard chemotherapy and radiation for locally advanced cervical cancer that cannot be removed by surgery. The study aims to see if this combination is safe and effective.

Changsha, Hunan
NCT07796789Recruiting· Phase 3
Preventing appetite loss during cancer treatment for nasopharyngeal carcinoma

This trial tests whether a medicine called nanocrystalline megestrol acetate can help prevent loss of appetite caused by chemotherapy and radiation therapy in people with nasopharyngeal carcinoma. If you are receiving chemoradiotherapy for this type of cancer, you may be able to participate.

Guangzhou, Guangdong
NCT07408505Recruiting
New appetite drug for weight loss in advanced pancreatic cancer

This trial tests a new form of a drug (nano-megestrol acetate) to help people with advanced pancreatic cancer who are losing weight and have poor appetite. It aims to see if it can improve cachexia, a condition of severe weight loss and muscle wasting.

Jinan
NCT06961188Not yet recruiting· Phase 3
A medicine to improve appetite for advanced lung cancer

This study tests a medicine called nanocrystalline megestrol acetate to see if it can help improve appetite and promote weight gain in people with advanced non-small cell lung cancer who are losing weight. If you qualify, you would receive this treatment alongside your regular care to help you feel better and maintain your strength.

Wuhan, Hubei

Hear when a new Hepatocellular Carcinoma (HCC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.